Fundz

Who to call at Nxera Pharma, and when

Fundz watches for the moments Nxera Pharma starts buying, and tells you who to reach.

  • An alert the day Nxera Pharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Nxera Pharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nxera Pharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

AbbVie secures exclusive licensing rights to Nxera’s EP4 program for inflammatory bowel disease with a $100 million payment.

Nov 04, 2026

Contract Type

partnership

CambridgeBiotechnologyHealth Care

Description

AbbVie is acquiring Nxera Pharma's EP4 receptor agonist program for inflammatory bowel disease for $100 million upfront and potential milestone payments of up to $1.37 billion. This partnership aims to develop and commercialize an oral small molecule, NXE0033744, to better address patient needs in IBD.

Company Information

Company

Nxera Pharma

Location

Cambridge, England, United Kingdom

About

Nxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products. Powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage.

Predictive Intelligence
Strategic

ML-powered predictions for Nxera Pharma's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Nxera Pharma signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.